Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aptinyx Inc (APTX)

Aptinyx Inc (APTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 101,022
  • Shares Outstanding, K 33,562
  • Annual Sales, $ 6,570 K
  • Annual Income, $ -53,280 K
  • 60-Month Beta 0.00
  • Price/Sales 16.64
  • Price/Cash Flow N/A
  • Price/Book 0.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.46
  • Number of Estimates 4
  • High Estimate -0.38
  • Low Estimate -0.51
  • Prior Year -0.43
  • Growth Rate Est. (year over year) -6.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.61 +15.33%
on 10/14/19
4.08 -26.23%
on 09/20/19
-0.99 (-24.75%)
since 09/18/19
3-Month
2.61 +15.33%
on 10/14/19
4.25 -29.18%
on 09/12/19
-0.76 (-20.16%)
since 07/18/19
52-Week
2.61 +15.33%
on 10/14/19
27.36 -89.00%
on 11/02/18
-23.34 (-88.58%)
since 10/18/18

Most Recent Stories

More News
Aptinyx to Present Preclinical Data on Three Clinical-Stage NMDA Receptor Modulators at the 49th Annual Meeting of the Society for Neuroscience

Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced five upcoming poster...

APTX : 3.01 (-7.67%)
Lifshitz & Miller LLP Announces Investigation of Abeona Therapeutics Inc., Aptinyx Inc., James River Group Holdings, Ltd., The Chemours Company, Overstock.com, Inc., Greenland Acquisition Corporation and Wanda Sports Group Limited

Abeona Therapeutics Inc. (ABEO)

APTX : 3.01 (-7.67%)
CC : 15.15 (+0.13%)
JRVR : 36.67 (-0.37%)
OSTK : 10.82 (-4.33%)
Aptinyx (APTX) Alert: Johnson Fistel Launches Investigation into Aptinyx Inc.; Investors Suffering Losses Encouraged to Contact Firm

Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Aptinyx Inc. (NASDAQ: APTX) ("Aptinyx") for violations of federal securities laws.

APTX : 3.01 (-7.67%)
Bragar Eagel & Squire, P.C. is Investigating Aptinyx, Inc. (NYSE: APTX) on Behalf of Aptinyx Stockholders and Encourages Aptinyx Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against Aptinyx, Inc. (NYSE: APTX) on behalf of Aptinyx stockholders. Our investigation concerns whether Aptinyx has violated the federal securities...

APTX : 3.01 (-7.67%)
Aptinyx's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Aptinyx.

APTX : 3.01 (-7.67%)
Aptinyx to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Ashish Khanna,...

APTX : 3.01 (-7.67%)
Three Recent Preclinical Publications Highlight NMDA Receptor Activation Facilitated by Aptinyx's NYX-2925

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that preclinical data...

APTX : 3.01 (-7.67%)
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. ("Aptinyx" or "the Company") (NASDAQ: APTX) for violations...

APTX : 3.01 (-7.67%)
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. ("Aptinyx" or "the Company") (NASDAQ: APTX) for violations...

APTX : 3.01 (-7.67%)
Will Aptinyx Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Aptinyx.

APTX : 3.01 (-7.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft. Long term indicators fully support a continuation of the trend.

See More Share

Trade APTX with:

Business Summary

Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company's product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in...

See More

Key Turning Points

2nd Resistance Point 3.48
1st Resistance Point 3.25
Last Price 3.01
1st Support Level 2.89
2nd Support Level 2.76

See More

52-Week High 27.36
Fibonacci 61.8% 17.91
Fibonacci 50% 14.99
Fibonacci 38.2% 12.07
Last Price 3.01
52-Week Low 2.61

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar